Elite Pharmaceuticals (OTC: ELTP) revenue jumps 77% in fiscal 2026
Rhea-AI Filing Summary
Elite Pharmaceuticals reported sharply improved results for the fiscal year ended March 31, 2026. Consolidated revenues reached $148.9 million, an increase of $64.8 million, or about 77%, over the prior year. Income from operations was $49.1 million, up $29.5 million, or roughly 151%.
The company attributed the stronger operating income mainly to a full-year contribution from its Lisdexamfetamine product, revenues from Oxycodone Acetaminophen tablets launched during the year, and Naltrexone and Phentermine tablets sold exclusively under the Elite label, along with broad growth across its product lines.
Management will discuss these year-end 2026 results and recent business developments on a conference call scheduled for June 30, 2026 at 11:30 AM EDT, with domestic and international dial-in numbers and an audio replay link provided.
Positive
- Strong revenue growth: Fiscal 2026 consolidated revenues were $148.9 million, increasing $64.8 million or about 77% from the prior year, reflecting significant expansion of Elite’s generic product portfolio.
- Margin and earnings expansion: Income from operations rose to $49.1 million, up $29.5 million or roughly 151% year over year, indicating improved operating leverage from new and existing products.
Negative
- None.
Insights
Elite shows strong fiscal 2026 growth driven by new and expanded generics.
Elite Pharmaceuticals delivered substantial scale-up in fiscal 2026, with consolidated revenues of $148.9 million, up $64.8 million or about 77% year over year. Income from operations rose to $49.1 million, an increase of $29.5 million or roughly 151%, indicating improved operating leverage.
The filing ties this performance to a full-year contribution from Lisdexamfetamine, plus new launches such as Oxycodone Acetaminophen tablets and exclusive-label Naltrexone and Phentermine tablets. This suggests the company is broadening its generic portfolio and benefiting from products carrying meaningful volume or margin.
The planned conference call on June 30, 2026 will provide further color on these results and recent business developments. Subsequent SEC reports may detail sustainability of this growth, competitive dynamics for Lisdexamfetamine and pain products, and how the stronger operating income translates into cash flow and future investment capacity.
8-K Event Classification
Key Figures
Key Terms
Lisdexamfetamine medical
income from operations financial
Regulation FD Disclosure regulatory
forward-looking statements regulatory
cGMP technical
Earnings Snapshot
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported)
ELITE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction | (Commission | (IRS Employer | ||
| of incorporation) | File Number) | Identification No.) |
(Address of principal executive offices)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| OTCQB |
Item 2.02. Results of Operations and Financial Condition.
On June 29, 2026, Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) filed its year-end report on Form 10-K for the fiscal year ended March 31, 2026, and, thereafter, issued a press release announcing its financial results for that fiscal year. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.
As noted in the press release, the Company will host a conference call at 11:30 AM Eastern Daylight Time (EDT) on Tuesday, June 30, 2026, to provide a general business update. Elite will respond to various stockholder questions submitted prior to the call.
Conference Call Information
| Date: | June 30, 2026 |
| Time: | 11:30 AM EDT |
| Dial-in numbers: | 1-800-346-7359 (domestic) |
| 1-973-528-0008 (international) | |
| Conference number: | 98840 |
| Questions: | dianne@elitepharma.com |
| Financial questions by 7:00 PM EDT on Monday, June 29, 2026 | |
| Audio Replay: | https://elite.irpass.com/events_presentations |
Item 7.01 Regulation FD Disclosure.
The information disclosed in Item 2.02 above is incorporated into this Item 7.01. The information included in this Current Report on Form 8-K (including the exhibit hereto) is being furnished under Item 2.02, “Results of Operations and Financial Condition,” Item 7.01, “Regulation FD Disclosure” and Item 9.01 “Financial Statements and Exhibits” of Form 8-K. As such, the information (including the exhibit) herein shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such a filing. This Current Report (including the exhibit hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release dated June 29, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: June 29, 2026 | ELITE PHARMACEUTICALS, INC. |
| By: | /s/ Nasrat Hakim | |
| Nasrat Hakim, President and CEO |
Exhibit 99.1
Elite Pharmaceuticals, Inc. Reports Financial Results for the Fiscal Year Ended March 31, 2026
and Provides Conference Call Information
Conference Call Scheduled for Tuesday, June 30 at 11:30 AM EDT
Northvale, NJ – June 29, 2026: Elite Pharmaceuticals, Inc. (“Elite” or the “Company”) (OTCBB: ELTP), a specialty pharmaceutical company developing niche generic products, announced results for the fiscal year ended March 31, 2026 (“Fiscal 2026”).
Consolidated revenues for Fiscal 2026 were $148.9 million, an increase of $64.8 million or approximately 77% as compared to the comparable period of the prior fiscal year. Income from operations was $49.1 million, an increase of $29.5 million or approximately 151% from the comparable period of the prior year. The increase in income from operations was primarily attributed to Elite’s Lisdexamfetamine, initially launched at the end of the prior fiscal year, having a full year contribution, revenues from Oxycodone Acetaminophen tablets launched during Fiscal 2026, combined with Naltrexone tablets and Phentermine tablets being launched exclusively under the Elite label during Fiscal 2026 and strong overall growth throughout the Elite label product lines.
Conference Call Information
Elite’s management will host a conference call to discuss the year-end 2026 financial results and provide an update on recent business developments. Stockholder questions should be submitted to the company in advance of the call.
| Date: | June 30, 2026 |
| Time: | 11:30 AM EDT |
| Dial-in numbers: | 1-800-346-7359 (domestic) 1-973-528-0008 (international) |
| Conference number: | 98840 |
| Questions: | dianne@elitepharma.com Financial questions by 7:00 PM EDT on Monday, June 29, 2026 |
| Audio Replay: | https://elite.irpass.com/events_presentations |
The financial statements can be viewed for Elite’s Fiscal Year 2026 on Form 10-K here.
About Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and distributes niche generic products. Elite specializes in developing, manufacturing, and distributing oral, controlled-release drug products. Elite owns multiple generic products, which it distributes nationwide under the Elite Laboratories, Inc. label. Elite operates a cGMP and DEA-registered research, development, and manufacturing facility in Northvale, NJ. For more information, visit www.elitepharma.com.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, those related to the effects, if any, on future results, performance or other expectations that may have some correlation to the subject matter of this press release. Readers are cautioned that such forward-looking statements involve, without limitation, risks, uncertainties and other factors not under the control of Elite, which may cause actual results, performance or achievements of Elite to be materially different from the results, performance or other expectations that may be implied by these forward-looking statements. These forward-looking statements may include statements regarding the expected timing of approval, if at all, of products by the FDA, and the actions the FDA may require of Elite in order to obtain such approvals. These forward-looking statements are not guarantees of future action or performance. These risks and other factors are discussed, without limitation, in Elite’s filings with the Securities and Exchange Commission, including its reports on forms 10-K, 10-Q, and 8-K. Elite is under no obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
For Elite Pharmaceuticals, Inc.
Dianne Will, Investor Relations, 518-398-6222
Dianne@elitepharma.com
www.elitepharma.com